Ear drug delivery to get a boost from launch of hearing loss therapeutics company Decibel

VC firm Third Rock is funding (to the tune of $52 million) and assembling a team focused on fighting hearing loss with drugs, an effort that's sure to push the envelope when it comes to drug delivery and administration within the ear. Decibel Therapeutic's founders include Charles Liberman of Harvard Medical School, who studies the use of neurotrophins to restore synapses. The company promises to "combine recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques." GlaxoSmithKline's ($GSK) venture arm also participated in the Series A round. More from FierceBiotech

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.